|
Oct 4
|
Market Chatter: Sanofi Healthcare Suitors Revise Offers Amid Talc Liability Concerns
|
|
Oct 4
|
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
|
|
Oct 4
|
Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
|
|
Oct 4
|
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
|
|
Oct 4
|
Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
|
|
Oct 4
|
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
|
|
Oct 4
|
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
|
|
Oct 4
|
Sanofi’s rare disease drug finds yet another home
|
|
Oct 4
|
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo
|
|
Oct 4
|
Texas sues major PBMs, pharma companies over high insulin prices
|
|
Oct 1
|
Update: Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
|
|
Oct 1
|
Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
|
|
Oct 1
|
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
|
|
Sep 30
|
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
|
|
Sep 28
|
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
|
|
Jul 26
|
Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
|
|
Jul 26
|
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
|
|
Jul 25
|
AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment
|
|
Jul 25
|
Sanofi (SNY) Q2 2024 Earnings Call Transcript
|
|
Jul 25
|
Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season
|